AU2019337806B2 - Peptides and medical uses thereof - Google Patents

Peptides and medical uses thereof

Info

Publication number
AU2019337806B2
AU2019337806B2 AU2019337806A AU2019337806A AU2019337806B2 AU 2019337806 B2 AU2019337806 B2 AU 2019337806B2 AU 2019337806 A AU2019337806 A AU 2019337806A AU 2019337806 A AU2019337806 A AU 2019337806A AU 2019337806 B2 AU2019337806 B2 AU 2019337806B2
Authority
AU
Australia
Prior art keywords
ivr1
cys
cysteine
cha
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019337806A
Other languages
English (en)
Other versions
AU2019337806A1 (en
Inventor
Sandro De Falco
Davide ROSIELLO
Menotti Ruvo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anbition SRL
Original Assignee
Anbition SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anbition SRL filed Critical Anbition SRL
Publication of AU2019337806A1 publication Critical patent/AU2019337806A1/en
Application granted granted Critical
Publication of AU2019337806B2 publication Critical patent/AU2019337806B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2019337806A 2018-09-11 2019-09-11 Peptides and medical uses thereof Active AU2019337806B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102018000008493 2018-09-11
IT201800008493 2018-09-11
PCT/IB2019/057636 WO2020053772A1 (en) 2018-09-11 2019-09-11 Peptides and medical uses thereof

Publications (2)

Publication Number Publication Date
AU2019337806A1 AU2019337806A1 (en) 2021-05-13
AU2019337806B2 true AU2019337806B2 (en) 2025-08-14

Family

ID=64607074

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019337806A Active AU2019337806B2 (en) 2018-09-11 2019-09-11 Peptides and medical uses thereof

Country Status (8)

Country Link
US (1) US12441765B2 (enExample)
EP (1) EP3849582B1 (enExample)
JP (2) JP2022500465A (enExample)
KR (1) KR20210062649A (enExample)
CN (1) CN112996528B (enExample)
AU (1) AU2019337806B2 (enExample)
CA (1) CA3112169A1 (enExample)
WO (1) WO2020053772A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019340465B2 (en) * 2018-09-11 2025-08-14 Anbition S.R.L. Peptides and medical uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09510688A (ja) * 1993-12-15 1997-10-28 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム Ｃｘｃインタークリン分子のペプチド阻害剤
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
DE60118186T2 (de) 2000-05-12 2006-12-28 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
CA2695960A1 (en) * 2007-08-08 2009-03-12 The Board Of Regents Of The University Of Texas System Vegfr-1/nrp-1 targeting peptides
EP2723766A4 (en) * 2011-06-22 2015-05-20 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
BR112017018665A2 (pt) * 2015-03-02 2018-04-24 The Board Of Trustees Of The University Of Illinois peptídeos para inibição de angiogênese
US10463710B2 (en) * 2015-04-27 2019-11-05 Mackay Memorial Hospital Short synthetic peptide for the treatment and/or prophylaxis of autoimmune and inflammatory disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Ph.D. Thesis", 1 January 2007, article SALVATORE PONTICELLI: "New inhibitors of pathological angiogenesis", XP055590024 *
ANDREA CAPORALE ET AL: "Synthetic Peptide Libraries. From Random Mixtures to In Vivo Testing", CURRENT MEDICINAL CHEMISTRY, vol. 25, 16 July 2018 (2018-07-16), NL, XP055589643, ISSN: 0929-8673, DOI: 10.2174/0929867325666180716110833 *
SALVATORE PONTICELLI ET AL: "Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1", J. Biol. Chem. (2008) 283(49): 34250 - 34259 *
VALERIA CICATIELLO ET AL: "Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models", ONCOTARGET (2015) 6(12): 10563-10576 *

Also Published As

Publication number Publication date
EP3849582B1 (en) 2025-12-31
WO2020053772A1 (en) 2020-03-19
JP2024150757A (ja) 2024-10-23
CA3112169A1 (en) 2020-03-19
KR20210062649A (ko) 2021-05-31
US20220064216A1 (en) 2022-03-03
EP3849582A1 (en) 2021-07-21
CN112996528B (zh) 2025-01-07
US12441765B2 (en) 2025-10-14
JP2022500465A (ja) 2022-01-04
AU2019337806A1 (en) 2021-05-13
CN112996528A (zh) 2021-06-18

Similar Documents

Publication Publication Date Title
EP3231438B1 (en) Wt1 immunotherapy for intraocular angiogenic disease
US20200216495A1 (en) Tau aggregation peptide inhibitors
AU2019337806B2 (en) Peptides and medical uses thereof
KR20170122762A (ko) 혈관신생 억제용 펩타이드
AU2019340465B2 (en) Peptides and medical uses thereof
US9249185B2 (en) Peptides for promoting angiogenesis and an use thereof
US20130196925A1 (en) Compositions and methods useful in enhancement of memory
US20240173376A1 (en) Trem-1 inhibitors for the treatment of marfan syndrome
US20250154212A1 (en) Method of disrupting memory and lipopeptide for use in such method
WO2022162030A1 (en) Peptides for inhibiting angiogenesis
WO2024175887A1 (en) Compositions and methods of using c/ebp alpha sarna
EP3397271B1 (en) Compositions and methods for treating retinopathy
HK1245149B (en) Wt1 immunotherapy for intraocular angiogenic disease
HK40000030B (en) Compositions and methods for treating retinopathy
HK40000030A (en) Compositions and methods for treating retinopathy
HK1245149A1 (en) Wt1 immunotherapy for intraocular angiogenic disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)